CYTH News and Press, Cyclo Therapeutics Inc. From 05/17/21

Cyclo Therapeutics (CYTH): Q1 Net loss of $4M.The Company ended the quarter with approximately $15.5 million of cash.Press Release For further details see: Cyclo Therapeutics reports Q1 results

- Pivotal Phase 3 study of Trappsol ® Cyclo™ for Niemann-Pick Disease Type C (NPC) on track to commence enrollment and dosing in Q2 2021 - Company advancing Alzheimer’s Disease Phase 2 asset towards investigational new drug application (IND) filing antic...

Ms. Gorski brings more than two decades of communications and patient advocacy experience serving rare disease communities Formerly led global communications and patient advocacy strategies for lysosomal storage disorders at Sanofi Genzyme Cyclo Therapeutics, Inc. ...

Alzheimer's disease can largely be stabilized if one inhibits the formation of peroxynitrite, removes it, and partially reverses the damage that it does to the brain through oxidation and nitration. Anavex 2-73, Trappsol Cyclo, and GV-971 probably do all three. If this analysis is...

Cyclo Therapeutics (CYTH) announces the design of its protocol and is preparing to commence its pivotal Phase 3 study evaluating Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin, used intravenously, in the treatment of Niemann-Pick Disease type C1 ((NPC1)...

Patient enrollment on track to commence in Q2 2021 Global clinical protocol agreed with US Food and Drug Administration (FDA) and European Medicines Agency (EMA) Dual primary objectives agreed; FDA 4-Domain Niemann-Pick disease Type C-Severity Scale (4D-NPC-SS) and...

Cyclo Therapeutics ([[CYTH]] +2.0%) has received feedback from the U.S. FDA supporting the company’s development strategy to submit an initial new drug application application for a Phase 2 study of Trappsol Cyclo in the treatment of early Alzheimer’s disease.The ...

FDA feedback supports Company’s Phase 2 development strategy for Alzheimer’s disease asset; IND filing on track for H2 2021 Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnolo...

Insider buying increased significantly last week. Notable Insider Buys: Landec Corporation, Super League Gaming, Inc., Cyclo Therapeutics, Inc., Greenwich LifeSciences, Inc., and Hudson Global, Inc. Notable Insider Sells: Ulta Beauty, Inc., Facebook, Inc., Fidelity National Financ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Insiders are people who have access to private information about a company and can do something called insider buying . They include a company’s senior management, members of the board of directors and other importa...